Literature DB >> 7686495

Different signals mediate transforming growth factor-beta 1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells.

P Franzén1, H Ichijo, K Miyazono.   

Abstract

The effects of transforming growth factor-beta 1 (TGF-beta 1) on a human prostatic carcinoma cell line PC-3, and its subclone PC-3U, were investigated. Dose-dependent inhibition of [3H]thymidine incorporation in PC-3U cells was observed by addition of TGF-beta 1, although only 50% inhibition was obtained by high concentrations (12 nM) of TGF-beta 1. The growth inhibitory effects of TGF-beta 1 on PC-3 cells was insignificant. When 0.3 ng/ml of phorbol 12-myristate 13-acetate (PMA) was added together with TGF-beta 1, TGF-beta 1 inhibited growth of PC-3 cells (about 50% inhibition), and the growth inhibitory activity of TGF-beta 1 in PC-3U cells was enhanced (more than 90% inhibition). Affinity crosslinking studies revealed that both cell lines possess all of the three described forms of TGF-beta receptors. The intensities of the crosslinked bands were weaker in the PC-3 cells than in PC-3U cells, and those were not increased by the addition of PMA. The expression of the TGF-beta type II receptor mRNA did not change after the addition of PMA or TGF-beta 1. These results suggest that the effects of PMA involved downstream components of the signal transduction pathway of TGF-beta 1. TGF-beta 1 is known to stimulate the production of extracellular matrix proteins and to induce changes in the expression of nuclear transcription factor genes. In both PC-3 and PC-3U cells, TGF-beta 1 was found to stimulate the induction of fibronectin and plasminogen activator inhibitor-1 and the expression of junB mRNA, and PMA did not affect these responses. Thus, PC-3 and PC-3U cells, which are partially resistant to the growth inhibitory activity of TGF-beta 1, could still respond to TGF-beta 1 by extracellular matrix production, independent of PMA action. These results suggest that different signalling pathways mediate TGF-beta 1-induced growth inhibition and stimulation of extracellular matrix accumulation in these cells.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7686495     DOI： 10.1006/excr.1993.1156

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN： 0014-4827            Impact factor:   3.905


  19 in total

1.  Polyubiquitination of transforming growth factor β (TGFβ)-associated kinase 1 mediates nuclear factor-κB activation in response to different inflammatory stimuli.

Authors:  Anahita Hamidi; Verena von Bulow; Rosita Hamidi; Nicolas Winssinger; Sofia Barluenga; Carl-Henrik Heldin; Marene Landström
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

2.  Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells.

Authors:  W C Duivenvoorden; H W Hirte; G Singh
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

3.  Foxp3+-inducible regulatory T cells suppress endothelial activation and leukocyte recruitment.

Authors:  Elena Maganto-García; De-Xiu Bu; Margarite L Tarrio; Pilar Alcaide; Gail Newton; Gabriel K Griffin; Kevin J Croce; Francis W Luscinskas; Andrew H Lichtman; Nir Grabie
Journal:  J Immunol       Date:  2011-08-26       Impact factor: 5.422

4.  Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1.

Authors:  T A McCaffrey; S Consigli; B Du; D J Falcone; T A Sanborn; A M Spokojny; H L Bush
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3.

Authors:  Sofia Edlund; Shizhong Bu; Norbert Schuster; Pontus Aspenström; Rainer Heuchel; Nils-Erik Heldin; Peter ten Dijke; Carl-Henrik Heldin; Maréne Landström
Journal:  Mol Biol Cell       Date:  2003-02       Impact factor: 4.138

6.  Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA.

Authors:  Sofia Edlund; Maréne Landström; Carl-Henrik Heldin; Pontus Aspenström
Journal:  Mol Biol Cell       Date:  2002-03       Impact factor: 4.138

7.  Independent changes in type I and type II receptors for transforming growth factor beta induced by bone morphogenetic protein 2 parallel expression of the osteoblast phenotype.

Authors:  M Centrella; S Casinghino; J Kim; T Pham; V Rosen; J Wozney; T L McCarthy
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

8.  Modulation of transforming growth factor beta receptor levels on microvascular endothelial cells during in vitro angiogenesis.

Authors:  S Sankar; N Mahooti-Brooks; L Bensen; T L McCarthy; M Centrella; J A Madri
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

9.  TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancer.

Authors:  Yabing Mu; Reshma Sundar; Noopur Thakur; Maria Ekman; Shyam Kumar Gudey; Mariya Yakymovych; Annika Hermansson; Helen Dimitriou; Maria Teresa Bengoechea-Alonso; Johan Ericsson; Carl-Henrik Heldin; Marene Landström
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

10.  Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.

Authors:  Zoi Lanara; Efstathia Giannopoulou; Marta Fullen; Evangelos Kostantinopoulos; Jean-Christophe Nebel; Haralabos P Kalofonos; George P Patrinos; Cristiana Pavlidis
Journal:  Hum Genomics       Date:  2013-06-05       Impact factor: 4.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.